Key Points vTv Therapeutics has completed enrollment in its Phase 3 CATT1 study of cadisegliatin as an add-on treatment to insulin for adults with type…
October 05, 2026
October 02, 2026
Surrozen Clears FDA IND Hurdle for DME Drug, Unlocking $95.1 Million Financing Milestone
Key Points The FDA has cleared Surrozen’s investigational new drug application for SZN-8141, enabling clinical development in diabetic macular edema. Surrozen expects to dose the…
October 02, 2026
Addex Therapeutics Brings Back Drug Development Veteran Jean-Philippe Rocher to Advance Pipeline
Key Points Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and a member of its executive management team. Rocher brings more than 30…
October 02, 2026
AngioDynamics Backs Jacobi Hospital Study to Predict Pulmonary Embolism Thrombectomy Success
Key Points AngioDynamics and The PERT Consortium selected Jacobi Hospital in the Bronx, New York, for an ALPHA-PE Research Fund award. The independent, investigator-led study…
September 30, 2026
Capricor Shares Rise as Longer-Term Deramiocel Data Enter FDA Review
Key Points Capricor shares rose in early trading Tuesday after a World Muscle Society poster on 24-month deramiocel data became available. The analysis follows patients…
September 30, 2026
Blood Cancer Awareness Month: The Next Wave of Treatments Is Moving Deeper Into the Biology of Disease
From protein degradation and menin inhibition to targeted radiopharmaceuticals and off-the-shelf cell treatments, companies are testing new ways to treat blood cancers and overcome resistance….
Key Points Sagimet’s license partner Ascletis reported results from a Chinese Phase 3 open-label extension study of denifanstat in moderate to severe acne. Among 240…
September 30, 2026
Vanda Reports Positive Phase 3 HETLIOZ Results in Delayed Sleep-Wake Phase Disorder
Key Points HETLIOZ (tasimelteon) met the primary endpoint in Vanda Pharmaceuticals’ Phase 3 trial for delayed sleep-wake phase disorder (DSWPD). After 28 days, patients taking…
September 29, 2026
Corbus Pharmaceuticals Doses First Patient in Registrational CRB-701 Throat Cancer Trial
Key Points TEMPO-1 is a randomized study expected to enroll 250 patients with second-line or later OPSCC. The trial will compare CRB-701 with the investigator’s…
Key Points TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….
September 28, 2026
Microbot Medical Expands LIBERTY Sales Footprint, Targets Positive Gross Margins in 2027
Key Points for MBOT Investors Microbot is on track to have 12 U.S. sales territories by the end of 2026 and has hired three Area…
September 28, 2026
Daré Bioscience Adds U.S. Patent Protection for DARE-HPV as Phase 2 Trial Advances
Key Points Daré Bioscience announced a new U.S. patent covering topical lopinavir-and-ritonavir formulations for HPV-related cervical conditions. Daré holds an exclusive U.S. license to the…